巨和粒治疗恶性肿瘤患者化疗后血小板减少症的临床观察

Effects of treatment of chemotherapy-induced thrombocytopenia in patients of carcinoma with recombinant human interleukin-11

目的:观察重组人白细胞介素-11(巨和粒)治疗恶性肿瘤患者化疗后血小板减少的疗效和不良反应。方法:36例化疗后血小板减少的恶性肿瘤患者分为两组,A组(治疗组)19例使用巨和粒皮下注射1.5mg/d,连用5～12d;B组(空白对照组)17例只使用一般补血和提升血小板计数的普通药物。每周观察巨和粒对血小板计数的影响,连续观察3周。结果:化疗结束后A组血小板计数[(42.00±12.29)×109/L]明显低于化疗前[(192.00±73.56)×109/L](P<0.05),B组血小板计数[(44.58±11.74)×109/L]亦明显低于化疗前[(203.37±75.28)×109/L(P<0.05)。A组治疗1周和2周后血小板恢复正常水平的比例(42.11%、100.00%)均明显高于B组(0、11.76%),差异有统计学意义(P<0.01)。A组19例患者未出现明显恶心、呕吐、腹泻等不良反应,患者耐受性良好,未发生严重不良反应和不良事件。结论:巨和粒治疗恶性肿瘤化疗后血小板减少安全、有效,不良反应少,患者可以耐受。

Objective ： To investigate the effects of treatment of chemotherapy-induced thrombocytopenia in patients of carcinoma with recombinant human interleukin-11 （rhIL-11 ）. Methods ： Thirty-six patients of carcinoma with chemotherapy-induced thrombocytopenia were divided into two groups： group A （19 cases） and group B （17 cases）. Patients of group A were treated with rhlL-11, 1.5rag daily, injected hypodermicly for 5 - 12 days ; patients of group B were treated with conventional regime. Platelet count was observed weekly for three weeks. Resuits： Platelet count in group A and B were（42. 00 ± 12. 29） ×10^9 L-1, （44. 58 ± 11. 74）×10^9 L-1 and （ 192.00 ± 73.56）×10^9 L-1, （203.37 ± 75.28 ）×10^9 L-1 after and before chemotherapy respectively, compared them with those before chemotherapy , all decreased after chemotherapy （P 〈 0.05）. After therapy, platelet count increased and gradually recovered to normal level, the normalization rates of platelet count in group A and B were42. 11% , 0 % and 100.00% , 11.76% in the first and second week respectively, the differences between them were significant （P 〈 0.01 ）. Patients of group A tolerated well, no obvious nausea, vomiting, diarrhea and other adverse reactions took place. Conclusion ： Treatment of chemotherapy-induced thrombocytopenia in patients of carcinoma with recombinant human interleukin-11 was safe and effective.